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Clinical Phenotypes of Different MPZ (P0)
Mutations May Include Charcot–Marie–Tooth Type 1B,
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the crucial role P0 plays in the structure and function ofSan Jose, California 95119
peripheral nerve myelin (Giese et al., 1992; Martini et al.,10Laboratory of Neurogenetics
1995a, 1995b).Flanders Interuniversity Institute for Biotechnology
The P0 gene was initially cloned from rat (Lemke andBorn Bunge Foundation
Axel, 1985; Lemke et al., 1988), and its human homolog,University of Antwerp
MPZ, was shown to map to chromosome 1q22-q23Department of Biochemistry
(Hayasaka et al., 1993c). Allelic point mutations in MPZB-2610 Antwerpen
have been associated with both Charcot–Marie–ToothBelgium
type 1B (CMT1B), the chromosome 1–linked form of
CMT (Bird et al., 1982), and Dejerine–Sottas syndrome
(DSS) (reviewed by Patel and Lupski, 1994). CMT1 isSummary
characterized by peripheral nerve demyelination re-
sulting in progressive distal muscle atrophy and sym-Hereditarydemyelinatingperipheralneuropathiescon-
metrically decreased motor nerve conduction velocitiessist of a heterogeneous group of genetic disorders
(NCV) (Lupski et al., 1993). Clinical symptoms of CMTthat includes hereditary neuropathy with liability to
usually manifest within the first two decades of life. Thepressure palsies (HNPP), Charcot–Marie–Tooth dis-
related demyelinating neuropathy, DSS, has pathologicease (CMT), Dejerine–Sottas syndrome (DSS), and
features and clinical symptoms that overlap with CMT1,congenital hypomyelination (CH). The clinical classifi-
but which are more severe (i.e., NCV < 10 m/s; hypertro-cation of these neuropathies into discrete categories
phic nerves) and have an earlier age of onset (i.e., delaycan sometimes be difficult because there can be both
in motor milestones) (Dyck et al., 1993). DSS is a geneti-clinical and pathologic variation and overlap between
cally heterogeneous disorder with mutations found inthese disorders. We have identified five novel muta-
tions in the myelin protein zero (MPZ) gene, encoding both MPZ (Hayasaka et al., 1993b; Rautenstrauß et al.,
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Table 1. Summary of Novel MPZ Point Mutations
Patient Number Diagnosis Domain Genotype Mutation Type Amino Acid Change
511 CMT Extracellular Htz Missense Arg-69→Ser
1022 DSS Extracellular Htz Missense Arg-69→Cys
1040 DSS Transmembrane Htz Frameshift After Leu-145
1047 and 1048 DSS Extracellular Hmz Frameshift After Gly-74
1049 and 1050 CMT Extracellular Htz Frameshift After Gly-74
987 CH Intracellular Htz Nonsense Gln-186→stop
Abbreviations: Htz, heterozygous; hmz, homozygous.
1994) and PMP22 (Roa et al., 1993a; Ionasescu et al., clinical findings, pathologic findings, and early age of
onset supported a diagnosis of DSS. Patient 1040 was1995; Valentijn et al., 1995). Within the group of heredi-
tary motor and sensory neuropathies (HMSN), which noted to have gross motor delay in early childhood and
presented at age 8 with a severe, early onset peripheralincludes CMT, HNPP, and DSS, another neuropathy,
termed congenital hypomyelination (CH), has been iden- neuropathy. Based on his early onset, severity of clinical
presentation, and NCV findings, patient 1040 was diag-tified. Congenital hypomyelination is characterized clini-
cally by early onset in infancy of hypotonia, areflexia, nosed with DSS. Family HOU 374 (patients 1047–1050)
was evaluated when both children (1047 and 1048) fromdistal muscle weakness, and very slow NCV (Lyon, 1969;
Kennedy et al., 1977; Harati and Butler, 1985). In its a consanguineous mating were diagnosed with DSS
based on clinical presentation, physical exam, and ab-extreme form, it may present with severe joint con-
tractures or arthrogryposis multiplex congenita (Char- sence of NCVs. NCV findings in each parent (1049 and
1050) could be consistent with a mild CMT1 phenotype.nas et al., 1988; Boylan et al., 1992). In less severe cases,
because of the overlapping clinical presentation, it can Detailed clinical information for each patient can be
found in Experimental Procedures.be extremely difficult to distinguish between CH and
DSS based only on physical examination and electro-
physiologic studies. However, pathologic findings on Molecular Results
Heteroduplex analysis on a cohort of 100 unrelated pa-sural nerve biopsies can often differientiate between
these disorders as patients with CH lack both active tients diagnosed with various demyelinating peripheral
neuropathies was performed for exons 1–6 of the MPZmyelin breakdown and well-organized onion bulbs, have
absence of inflammation, and show hypomyelination of gene. Several patients showed altered patterns and
were further analyzed by DNA sequencing. Patient 1040most or all fibers (Ono et al., 1982; Harati and Butler,
1985; Balestrini et al., 1991). These features are not had a single faster migrating heteroduplex band, while
patient 1022 exhibited a single slower migrating hetero-prominent in DSS. While progress has been made with
regard to the molecular diagnosis of CMT1 and DSS, duplex band (data not shown). Patients 1047–1050 (fam-
ily HOU 374) showed a complex heteroduplex patternthere is no published data on the molecular analysis
of CH. consisting of three heteroduplex bands, one migrating
below the homoduplex and two migrating above (dataMutational analysis in patients with either CMT1B,
DSS, or CH has identified five novel MPZ mutations not shown). In addition, even though patients 511 and
987 were negative by heteroduplex analysis, an altered(Table 1). These mutations provide an excellent model
for understanding the etiology of these myelinopathies pattern was shown by single strand conformation poly-
morphism (SSCP) analysis (performed by E. N. in theand the correlation of disease type and severity with
mutation type and location to derive phenotype/geno- laboratory of C. V. B.) in MPZ exon 3 and exon 5, respec-
tively (data not shown) (Nelis et al., 1996). Heteroduplextype correlations.
analysis of the other five exons of MPZ, all four coding
exons of PMP22, and the large coding exon of Cx32
detected no other base alterations, except in patientResults
511 who has a silent polymorphism in MPZ exon 6 (Roa
et al., 1996).Patient Diagnoses
Patient 511 presented as an adult with a moderate pe- The precise DNA sequence alterations were identified
by direct sequence determination of both sense andripheral neuropathy. Clinical, electrophysiologic, and
family history supported a diagnosis of CMT1. Patient antisense strands of the involved exons. Patient 511 has
a heterozygous C→A transversion in exon 3 at nucleo-987 presentedearly in lifewith delayedmotor milestones
and severely reduced NCVs that indicated a generalized tide 292 that leads to an Arg-69→Ser amino acid substi-
tution (Figure 2C). HhaI restriction analysis confirmedperipheral neuropathy. A sural nerve biopsy was per-
formed to facilitate a more definitive diagnosis (Figure the presence of this mutation. Normally, HhaI cuts once
within the 310 bp exon 3 polymerase chain reaction1). Based onthe clinical presentation, physical examina-
tion, electrophysiologic, and pathologic findings, patient (PCR) product to yield two fragments of 120 bp and 190
bp. However, the C→A mutation destroys the HhaI site987 was diagnosed with CH. Patient 1022 was self-
referred at age 42 because of a persistent, but nonpro- and results in the presence of the 310 bp uncut product.
BsaHI digestion was used as a control (data not shown).gressive unsteady gait, balance disturbance, and poor
fine motor skills. Her past medical history, severity of The base change in exon 5 of patient 987 consists of
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Figure 1. Electron Micrograph of Sural Nerve
Biopsy of Patient 987
This electron micrograph shows two axons
of similar size, one without myelin (a) and the
other with a thin myelin sheath (b) showing
stretches of noncompaction next to the axon
(arrows). The axon without myelin (a) is sur-
rounded by a Schwann cell with copious cy-
toplasm, which has partially wrapped the
axon with a single process. Another Schwann
cell without an axon is located nearby (c).
Original magnification: 25,0003.
a C→T transition at nucleotide 643 that generates a seen in 100 unrelated controls, which indicates that both
mutations at codon 69, in patients 511 and 1022, arepremature stop in the Gln-186 codon (Figure 2B). The
mutation results in the elimination of a BsoFI restriction disease associated and not common polymorphisms.
The mutation in patient 1040 occurs in exon 4 andsite. BsoFI cuts thewild-type 210 bp exon 5 PCR product
into 170 bp and 40 bp fragments. Digestion of patient consists of a heterozygous 4 bp deletion of nucleotides
521–524 that results in a frameshift after Leu-145. This987 results in the formation of three bands: 210 bp (uncut
mutant allele), 170 bp, and 40 bp (wild-type allele) (data frameshift alters the amino acid sequence of the last 74
codons and produces a protein that is one amino acidnot shown). HhaI digestion was used as a control. BsoFI
digestion of the parents, aswell as 99 unrelated controls, longer than wild type. A deletion was identified by direct
sequencing of PCR-amplified genomic DNA. However,showed only 170 bp and 40 bp fragments, which indi-
cates that this is a disease-associated mutation. The the exact nature of the deletion could not be determined
by direct sequencing because of the presence of bothabsence of parental mutations and confirmation of pa-
ternity demonstrates that patient 987 carries a de novo the deleted and undeleted copies in the same lane.
Therefore, the exact four base pairs deleted were deter-mutation.
Patient 1022 carries a heterozygous C→T transition mined by fluorescent automated sequencing of cloned
PCR products (Figure 3). Parental DNA was unavailableat the same nucleotide position as patient 511; however,
this mutation predicts an Arg-69→Cys amino acid sub- for analysis.
Direct sequence determination of exon 3 identifiedstitution (Figure 2A). Direct sequencing of both unaf-
fected parents revealed only wild-type sequence. This the base change in family HOU 374 as a 1 bp deletion
of nucleotide 306 that leads to a frameshift after themutation was also confirmed by the HhaI digestion used
for patient 511. Only patient 1022 showed the presence Gly-74 codon and a premature truncation of the protein
13 codons later. The children, 1047 and 1048, are homo-of three bands when cut with HhaI (data not shown).
The absence of parental mutations and confirmation of zygous for this allele as indicated by Figure 2D. The
heterozygosity of the parents, 1049 and 1050, was con-paternity demonstrates that patient 1022 carries a de
novo mutation. The destruction of the HhaI site was not firmed by fluorescent automated sequencing of cloned
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Figure 2. Direct Sequence Identification of
MPZ Mutations
Pedigrees and relevant sequences of four
families with various demyelinating periph-
eral neuropathies. Standard pedigree sym-
bols are used; disease is indicated by dark-
ened symbols.
(A) Sense strand sequence of the MPZ exon
3 region containing the C→T transition in pa-
tient 1022 (arrow). Both unaffected parents
are wild type.
(B) Sense strand sequence of the MPZ exon
5 region containing the C→T transition in pa-
tient 987 (arrow). Both parents are wild type.
(C) Sense strand sequence of the MPZ exon
3 region containing the C→A transversion in
patient 511 (arrow).
(D) Antisense strand sequence of the MPZ
exon 3 region containing the homozygous 1
bp deletion in patients 1047–1048 (arrows).
PCR products, which separately identified the wild-type paper, CH (Figure 4). As mutations associated with DSS
are most often found in the heterozygous state, theyand mutant alleles (data not shown). The homozygosity
or heterozygosity were additionally confirmedby restric- represent dominant alleles and not recessive as origi-
nally thought (Hayasaka et al., 1993b; Roa et al., 1993a).tion analysis. The 1 bp deletion creates a novel BslI
restriction site that cuts the wild-type 330 bp exon 3 In fact, the overwhelming majorityof DSS cases in which
a mutation has been identified represent de novo pointPCR product into 195 bp and 135 bp fragments. BsaHI
digestion was used as a control. Digestion of 100 unre- mutations in either MPZ or PMP22. The identification of
these 29 MPZ point mutations in patients with peripherallated controls with BslI resulted in only the 330 bp wild-
type band that indicates a disease-associated mutation neuropathies enables deductions regarding genotype/
phenotype correlations in these disorders. Figure 4(data not shown).
shows the amino acid changes associated with each
MPZ mutation and the corresponding clinical pheno-Discussion
type. Structural studies of the rat P0 protein (Shapiro
et al., 1996), which manitains 97% primary sequenceGenotype/Phenotype Correlations
To date, 29 point mutations in MPZ have been identified conservation with its human counterpart, allow predic-
tions to be made with respect to the effects individualthat result in either CMT1B, DSS, or as reported in this
Figure 3. Printout of Sequence from the Ap-
plied Biosystem DNA Sequencer for Patient
1040
The sense strand DNA sequence for the rele-
vant region of MPZ exon 4 is shown.
(A) The deleted allele with the site of the de-
leted bases indicated by a veritcal arrow.
(B) The normal allele with the four deleted
bases indicated by brackets. The predicted
amino acid sequence of each allele is shown,
and the frameshift is denoted by an horizontal
arrow.
Genotype/Phenotype Correlations in MPZ Mutations
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Figure 4. Structure of P0 and Summary of
Identified MPZ Mutations
Amino acids are numbered based on the pro-
cessed protein, and amino acid residue num-
bers are enclosed within parentheses. Yellow
circles correspond to amino acid substitu-
tions causing CMT1B, while the pink circles
indicate amino acid substitutions associated
with DSS. The delta symbol indicates an
amino acid deletion (del), and the X mark indi-
cates nonsense mutations. Frameshift (fs)
mutations are indicated by a slash mark pre-
ceding the first amino acid affected in the
reading frame, and the listing at the bottom
indicates the last unaffected amino acid be-
fore the frameshift. Numbers 1–23 result in
CMT1B (yellow). Number 12, Trp(72)Cys, and
number 23, Val(203)fs, are denoted by a pink
number sign to indicate that these substitu-
tions result in a phenotype that could be more
consistent with DSS than severe CMT1B.
Number 5, Phe(35)del, and number 13,
Gly(74)fs, are denoted by a pink *hmz sign to
indicate that in the homozygous state these
mutations result in a DSS phenotype. Num-
bers 24–28 (pink) are associated with DSS.
Number 29 (blue) results in CH. References
are as follows: 1 (Hayasaka et al., 1993e); 2
(Gabree¨ls-Festen et al., 1996); 3 (Kulkens et
al., 1993); 4 (Blanquet-Grossard et al., 1995);
5 (Ikegami et al., 1996); 6 (Nelis et al., 1994b;
Latour et al., 1995); 7 (Himoro et al., 1993); 8
and 9 (Hayasaka et al., 1993a); 10 (Hayasaka
et al., 1993d; Gabree¨ls-Festen et al., 1996); 12
(Latour et al., 1995); 14 (Blanquet-Grossard et
al., 1996); 15 (Gabree¨ls-Festen et al., 1996;
Tachi et al., 1996); 16 (Nelis et al., 1994a); 17,
21, and 22 (Nelis et al., 1994b); 18 and 20
(Roa et al., 1996); 19 (Gabree¨ls-Festen et al.,
1996); 23 (Bellone et al., 1996); 24 and 26
(Hayasaka et al., 1993b); 25 (Gabree¨ls-Festen
et al., 1996; this work); 28 (Rautenstrauß et
al., 1994); 11, 13, 25, 27, and 29 (this work).
extracellular mutations may have on the processing, are consistent with our proposed model (Shapiro et al.,
1996). Two other cysteine substitutions in the extracellu-structure, and protein interactions of P0 and enable cor-
relations with disease severity. lar domain, Tyr-53→Cys (Himoro et al., 1993) and Trp-
72→Cys (Latour et al., 1995), were reported in CMT1BThere are two instances wherein different mutations
at the same amino acid location within P0 (positions 34 patients. While this finding appears inconsistent with
our proposed mechanism, the tyrosine side chain at[Hayasaka et al., 1993b; Kulkens et al., 1993; Blanquet-
Grossard et al., 1995] and 69 [Hayasaka et al., 1993d; position 53 is buried in the hydrophobic core (Figure 5)
(Shapiro et al., 1996), and the substituted cysteine isGabree¨ls-Festen et al., 1996; this manuscript]) produce
distinct phenotypes (CMT1B or DSS). These position- likely unavailable to form disulfide bonds. However, the
sulfhydryl group of the cysteine substitution at positionspecific mutations provide an excellent model for exam-
ining how disease severity correlates with mutation ef- 72 is exposed (Figure 5). If one considers CMT1B and
DSS as similar disorders with a spectrum of severity,fect. Both DSS mutations arise from cysteine substitu-
tions that, based on structural data, would produce out- then the description by Latour et al. (1995) of a patient
who has an early onset of disease and an NCV of 10wardly pointing thiols (Figure 5). We postulate that these
outwardly pointing thiols produce a dominant negative m/s may represent either severe CMT1 or DSS. There-
fore, the severe phenotype conveyed by this mutationeffect through the formation of disulfide aggregates in
the extracellular space that possibly “poison” the myelin could beconsidered consistent with the proposed domi-
nant negative effect of the substituted cysteine residues.structure by forming abnormal P0 complexes that incor-
porate both normal and abnormal subunits and severely The corresponding less severe CMT1B mutations, at
positions 34 (Kulkens et al., 1993; Blanquet-Grossard etreduce the number of normal multimeric P0 complexes.
Our model of a dominant negative mechanism requires al., 1995) and 69 (Hayasaka et al., 1993d; Gabree¨ls-
Festen et al., 1996; this manuscript), may constitutea multimeric P0 complex. The structural data, which sug-
gest the formation and interaction of homotetramers, loss-of-function alleles. The deletion at position 34 (Kul-
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are well documented in osteogenesis imperfecta (OI),
a disorder of type I collagen. OI type 1 results from
heterozygous mutations in the a1(I) gene that prohibit
incorporation of abnormal protein into the collagen mol-
ecule or reduce the amount of protein available (i.e.,
loss of function), thereby causing a 50% loss in the
amount of normal collagen. OI type II is the most severe
lethal form and is due to de novo heterozygous a1(I)
mutations that cause the mutant collagen peptide to act
in a dominant negative manner by incorporating into the
multimeric collagen triple helix tocause a 75%reduction
in the amount of normal collagen (Byers et al., 1991).
Therefore, dominant negative mutations in a protein in-
volved in a multimeric complex disrupt the macromolec-
ular structure more than heterozygous loss-of-function
mutations and thus produce a more severe phenotype.
Identification of a Homozygous Mutation
Of particular interest is the identification of potentially
homozygous null MPZ patients. The Gly-74 frameshift
mutation in patients 1047–1050, resulting from a 1 bp
deletion, leads to a premature stop that predicts a trun-
cated protein of only 87 amino acids. This truncated
protein is presumably degraded and never reaches the
membrane. Therefore, this mutation is similar to the
above mentioned nonsense mutations and probably
constitutes a loss-of-function allele. In this family, the
parents, who are heterozygous for the 1 bp deletion,
have a mild neuropathy with features of CMT1. The chil-
dren who are homozygous for the same 1 bp deletion,Figure 5. Crystal Structure of the P0 Extracellular Domain Showing
the Residues That Are Mutated to Cysteines which essentially represents a null allele for MPZ, pres-
ent with a DSS phenotype. This phenotypic variationAn alpha carbon worm representation of the crystal structure of the
P0 extracellular domain (with a model for a disordered region colored seen between the heterozygous and homozygous state
in green) is shown with side chains drawn for residues that have closely resembles that seen in P0 knockout mice (Martini
known disease phenotypes when mutated to cysteine (Shapiro et et al., 1995b). Young adult P01/2 mice, between 4–10al., 1996). Ser-34 (S34) and Arg-69 (R69), colored pink, have side
weeks of age, show normal myelination. However, mor-chains that are directed outward; mutation of these residues to
phological abnormalities, like demyelination and onioncysteine results in DSS. Mutation of Tyr-53 (Y53) and Trp-72 (W72)
bulb formation, are first detected at 4 months of ageto cysteine reportedly results in CMT1 (yellow). The side chain of
Tyr-53 is buried in the core of the protein, but Trp-72 is partly and become more evident at 1 year of age. These abnor-
directed toward the solvent. The pink asterisk next to Trp-72 (W72*) malities lead to moderate electrophysiologic alterations
indicates that based on the clinical symptoms this mutation may (Martini et al., 1995b). This demonstrates that only half
represent either severe CMT or DSS.
the normal dose of P0 is sufficient to begin myelination,
but apparently is not enough to support myelin mainte-
nance at a later age. The resulting late onset and mildkens et al., 1993) falls within a b strand and may disrupt
its in (hydrophobic)–out (hydrophilic) alternation, caus- phenotype resembles the phenotype of CMT1B patients
(Martini et al., 1995b). On the other hand, P02/2 (null) miceing an unstable protein. Ser-34 is near an apparent site
of P0–P0 homotetramer interactions. Substitution to phe- develop abnormal, poorly compacted myelin from the
onset of myelin formation, probably owing to the lossnylalanine (Blanquet-Grossard et al., 1995), which has
a largehydrophobic side chain, might prevent the forma- of the adhesive properties of P0 (Martini et al., 1995b).
These P0-deficient mice have myelin decompaction attion of a fully functional network of molecules, possibly
resulting in a partial decrease in myelin compaction 4 days after birth that results in pronounced electrophys-
iologic and pathologic changes that are strikingly similar(Shapiro et al., 1996). The histidine and serine substitu-
tions at position 69 may disrupt the interaction between to those in severely affected CMT1B and DSS patients.
Therefore, P0 heterozygous and homozygous knockoutP0 proteins that is important for the formation of the
homotetramer (Shapiro et al., 1996). The identification mice are excellent models for understanding the role P0
plays in human myelination.of nonsense mutations, at positions 125 and 152 (Nelis et
al., 1994b), associated with a CMT1B phenotype, further The presentation of the HOU 374 family is similar to
that discussed by Ikegami et al. (1996) and to the homo-supports the postulation that the above mentioned mu-
tations represent loss-of-function alleles, since the re- zygous 17p duplication cases reported for CMT1A (Kil-
lian and Kloepfer, 1979; Lupski et al., 1991; Kaku et al.,sulting truncated proteins probably never reach the
membrane. 1993). In each of these cases, the heterozygous parents
presented with CMT1, while the homozygous childrenExamples of such genotype/phenotype correlations
Genotype/Phenotype Correlations in MPZ Mutations
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were more severely affected with DSS. The differences However, those mutations that produce a truncated
product of 120 residues or longer result in a severein clinical phenotype between heterozygous mutations
(CMT1) and homozygous mutation (DSS) in both MPZ dominant b-thalassemia. The severity of the phenotype
presumably reflects the properties of the mutant proteinand PMP22 not only demonstrates the dosage sensitiv-
ity of these myelin genes, but also further supports the that allow it to still bind heme, but also resist proteolytic
degradation due to secondary structure and thus allowhypothesis that these clinical “entities” represent vari-
ants of the same disease. the mutant to form aggregates (Thein et al., 1990).
The three other intracellular mutations in MPZ are all
frameshifts that generate proteins that are slightly largerMutation Associated with CH
than wild type, produce different intracellular amino acidThis manuscript describes a mutation, Gln-186→stop,
conformations, and manifest as severe neurologicalassociated with the diagnosis CH (patient 987). There
phenotypes. It has been shown that the highly positivelyhas been some controversy and difficulty in differentiat-
charged P0 intracellular domain interacts with the nega-ing CH from DSS, since there is considerable overlap
tively charged phospholipid bilayer to help form the ma-in clinical presentation. Based on pathologic findings
jor dense line (Ding and Brunden, 1994). Posttransla-of sural nerve biopsies (the absence of active myelin
tional phosphorylation of the intracellular domain maybreakdown and the paucity of the onion bulbs in CH
regulate its affinity for the phospholipid bilayer (Suzukiand the presence of demyelination/remyelination and
et al., 1990). The fact that changing either the entirean abundance of well-organized onion bulbs in DSS
intracellular conformation (i.e., the Leu-145 frameshift)[Balestrini et al., 1991]), CH is considered to result from
or only the last 16 amino acids (i.e., the Val-203a congenital impairment in myelin formation, while DSS
frameshift) produces a severe neurological phenotypeis thought to be due to abberrant demyelination and
suggests that even slight alterations of the charge profilesubsequent remyelination of the peripheral nerve. There
can interfere with the formation and compaction of theis also variation in the prognosis of patients diagnosed
major dense line. This conclusion is supported by find-with CH. Harati et al. (1985) showed correlation of mor-
ings demonstrated for the myelin basic protein (MBP),bidity and mortality with the presence/absence of onion
an intracellular positively charged protein capable ofbulbs. Patients with few onion bulbs died in early in-
interactions with phospholipid bilayers and responsiblefancy, usually because of difficulty in swallowing and
for the compaction of the major dense line in the CNS,respiration after birth. Patients with atypical onion bulbs,
wherein small changes in the net charge markedly al-similar to patient 987, survived but were affected with
tered the interaction of the protein with the lipid andsevere motor and sensory impairment (Harati and Butler,
affected vesicle aggregation (Cheifetz et al., 1985;1985). These differences in outcome may represent ge-
Cheifetz and Moscarello, 1985).netic heterogeneity such that mutations in essential
early myelin gene(s) cause a severe phenotype, while
mutations in other, possibly later acting gene(s), like Conclusions
MPZ, lead to a less severe outcome. Nevertheless, our CMT1, DSS, and CH represent a spectrum of genotypi-
observation of a P0 mutation associated with a CH phe- cally related entities resulting from mutations in a num-
notype suggests that a severe allele of a major myelin ber of genes (including MPZ) involved in myelination.
protein component can have dramatic effects on myelin The phenotype is dependent upon the gene in which
structure and formation. the mutations occur, the nature of the mutation, the
effect the mutation has on the gene and protein product,
and the consequence of that change on myelination.Mutations Associated with the MPZ
Intracellular Domain The data presented in this manuscript support the pos-
tulation that these peripheral neuropathies are not nec-There are five mutations that affect the intracellular do-
main of MPZ (numbers 22, 23, and 27–29 in Figure 4). The essarily distinct pathophysiologic entities, but instead
represent a spectrum of related clinical findings. Molec-severity of most of the intracellular mutations suggests it
plays an important functional role for myelin. The Tyr- ular evaluation of patients with inherited peripheral neu-
ropathies will not only complement the clinical, electro-152 nonsense mutation (Nelis et al., 1994b) results in a
CMT1 phenotype and, as discussed earlier, probably physiologic, and pathologic findings, but will more
precisely define the etiology and pathogenesis of theserepresents a loss-of-function allele. However, the sever-
ity of the phenotype (i.e, CH) resulting from the Gln-186 disorders.
We hypothesize that the variation in clinical severitynonsense mutation agrues that instead of a loss-of-
function allele, the resulting protein maintains some caused by different mutations in MPZ can be explained
by the different effects of each mutation. We proposefunction that interferes with the normal function of P0,
in particular the formation of the major dense line. The that heterozygous loss-of-function mutations reduce
the total amount of normal protein present, thus produc-correlation between placement of nonsense mutations
within the protein and the severity of the disease has ing a less severe CMT1B phenotype, while dominant
negative mutations, which disrupt the formation oralso been documented in b-thalassemia. It has been
shown that nonsense or frameshift mutations that pro- proper functioning of the P0 complex, or homozygous
loss-of-function mutations, which completely lack theduce truncated proteins that are up to 72 residues in
length usually produce a mild phenotype in heterozy- P0 protein, result in a more severe DSS or CH phenotype.
Such hypotheses need to be further investigated bygotes. It is thought that these short fragments are de-
graded, and only half the normal b-globin is synthesized. biochemical methods to determine the exact effect each
Neuron
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ulnar nerves. A sural nerve biopsy showed a severe demyelinating–mutation has on the processing, structure, or interac-
remyelinating neuropathy with evidence of a mild secondary axonaltions of P0.
degeneration. Teased nerve preparations revealed changes of de-
myelination and remyelination involving 80% of myelinated fibers.
Experimental Procedures
There was no evidence of inflammation, and onion bulbs were identi-
fied by light microscopy of semithin sections stained with toluidine
Patient Evaluations
blue.
A cohort of 100 unrelated patients, who carried a diagnosis of a
Patient 1040 was born by Cesarean section to a family with no
demyelinating peripheral neuropathy according to widely accepted
history of neurological disorders. By history, he was a floppy baby.
diagnostic criteria (Dyck et al., 1993), was analyzed for mutations
At 6 months, he was noted to be hypotonic, and in early childhood
in three genes known to be associated with peripheral neuropathies
had gross motor delay that included no head control until after 1
(MPZ, PMP22, and Cx32). All patients were found to be negative
year and not walking alone until between the ages of 2 and 3. He
for the CMT1A duplication on chromosome 17p11.2-p12 (Wise et
was evaluated by a neurologist at 8 years of age and found to
al., 1993). Patients positive for a MPZ mutation by heteroduplex
have atrophy and mild weakness of the hands, marked distal leg
analysis were further evaluated. The clinical findings of patients 511,
weakness, absent deep tendon reflexes, and sensory loss. NCV
987, 1022, 1040, and 1047–1050 are discussed below. Given the
studies showed no elicited response in the sensory nerves of the
apparent de novo nature of the disease in patients 987 and 1022,
median, ulnar, and left posterior tibial nerves and prolongation of
DNA-based paternity testing was performed by Identigene (Hous-
motor latency with decreased amplitude in both the median and
ton, TX) and yielded a probability of paternity of at least 99.4252%
ulnar nerves. A sural nerve biopsy was deferred by the parents.and 99.99952%, respectively. Parental DNA was unavailable for pa-
Patients 1047–1050 (family HOU 374) were evaluated when both
tient 1040.
children (1047 and 1048) were diagnosed with DSS. The parents
Patient 511 was self-referred because of a family history of CMT1
(1049 and 1050) are distantly related (coefficient of consanguinity:
in her father and paternal grandmother and a history of “toe walking”
1/512) and were found to have a mild chronic neuropathy with fea-
since age 3 and “flat feet.” Physical examination at age 20 revealed
tures of CMT1. Based on the severity of the clinical presentation
pes planus, severe distal muscle atrophy, foot drop, absent deep
and the consanguineous mating, the children were suspected to be
tendon reflexes, decreased sensation in the distal lower extremities,
homozygous for the mutation carried by their parents.
and mild distal upper extremity weakness. Electrophysiology
Patient 1048 is the first child born to 1049 and 1050. He had
showed slowed NCVs (right ulnar nerve, 13 m/s; right median nerve,
delayed acquisition of motor milestones (i.e., could not sit, stand,
11 m/s; unobtainable motor conductions and sensory nerve action
or walk at 1 year of age). Upon examination at age 17, he was found
potentials [NAP] in the lower extremities). A sural nerve biopsy was
to have bilateral pes cavus, scoliosis, clawed hands, severe muscle
not performed.
wasting, hypotonia, areflexia, and absent vibration sensation below
Patient 987 was first evaluated by a neurologist at 10 months
the shoulders. He relies upon a wheelchair for mobility because of
because of delayed motor milestones. She was the product of a
severely impaired strength.Nerve conduction studies demonstrated
normal pregnancy and delivery and had no family history of neuro-
absence of both sensory and motor action potentials. A sural nerve
logical disorders. Clinical evaluation revealed mild hypotonia of the biopsy, performed at age 5, showed a hypertrophic neuropathy with
limbs and trunk and absent stretch reflexes. She could not lift her
onion bulb formation. There was severe thickening of the nerve,
head while prone, but could sit if placed. Nerve conduction studies
massive demyelination and thinning of the fibers, massive increase
revealed a generalized demyelinating neuropathy (left median, 6
in the number of Schwann cells with onion bulbs, and increased
m/s; right ulnar, 6 m/s), and sensory action potentials were absent.
amounts of interstitial endoneural tissue.
By 18 months of age, she was crawling and stood with support, by
Patient 1047 was the second child born to 1049 and 1050. He
20 months she could pull to stand, and by 3.5 years she could take
had delayed acquisition of motor milestones (i.e., sat independently
a few steps unassisted. Scoliosis was diagnosed at age 3. A sural
at 8 months, crawled at 1 year, and walked at 3.5 years). Upon
nerve biopsy performed at 18 months revealed abnormally thin my-
examination at age 10, he was found to have bilateral pes cavus,
elin sheaths with mild reduction in the number of myelinated fibers
palpable ulnar nerves, muscle hypotonia, uniformly diminished
(Figure 1). No Wallerian degeneration was visible, and no macro-
strength, areflexia, and diminished vibration sense. He was unable
phages were seen. Rare rudimentary onion bulbs were seen by
to stand without support and had a steppage gait that was unsteady.
electron microscopy. The myelin sheaths were segmentally or cir-
Nerve conduction studies demonstrated absence of both sensory
cumferentially uncompacted (Figure 1). Occasionally relatively large
and motor action potentials. No sural nerve biopsy was performed.
axons were found that had no myelin, but instead were surrounded
Patient 1049 was not clinically assessed prior to the evaluation
by Schwann cells with copious cytoplasm (Figure 1). These findings
of her children. Upon examination at age 34, she had bilateral pes
were attributed mainly to a lack of development of proper myelin cavus with varus deformity. Muscle bulk and strength were normal.
rather than the result of demyelination and failure of remyelination.
Deep tendon reflexes were present in the upper extremities, but
A lumbar puncture revealed a cerebrospinal fluid (CSF) protein of
diminished in the lower extremities. Both motor and sensory nerve
75 mg%. Additional NCV studies performed at ages 6 and 8 con-
conduction velocities were mildly delayed (motor: leftperoneal, 31.5
firmed the finding at age 10 months of severe motor slowing (i.e.,
m/s; left ulnarm 44.2 m/s; sensory: left sural, 35.0 m/s; left median,
age 6: left median, 9 m/s; left ulnar, 9 m/s; age 8: left median, 4 m/s;
47.1 m/s). The NCV findings could be consistent with a mild CMT1
left ulnar, 5 m/s). NCVs on her parents were normal.
phenotype.
Patient 1022 was the product of an uncomplicated pregnancy
Patient 1050 was not clinically assessed prior to the evaluation
and delivery. She had delayed acquisition of motor milestones, did
of his children. Upon examination at age 41, he had bilateral mild
not walk until age 2, and had balance problems throughout child-
atrophy of the gastrocnemiusmuscles, pronounced distal hypesthe-hood. She was diagnosed with scoliosis at age 12. She had no
sia for light touch, sharp and dull discrimination, elevated vibratoryfamily history of neurological abnormalities, and her parents and
thresholds in the feet, and markedly reduced deep tendon reflexesbrother had normal NCVs. On presentation, she was found to have
in the lower extremities. Both motor and sensory nerve conductionwide based unsteady gait, mild to moderate dextroscoliosis, atrophy
velocities were mildly delayed (motor: left peroneal, 29.5 m/s; rightof the interosseous muscles of the hands, and bilateral pes cavus
ulnar, 44.4 m/s; sensory: left sural, 30.5 m/s; left median, 33.6 m/s).deformity. Deep tendon reflexes were absent, and there was loss
The NCV findings could be consistent with a mild CMT1 phenotype.of distal proprioception and vibratory sense in the upper and lower
extremities bilaterally. There was distal limb weakness and de-
Molecular Analysiscreased sensation distally to pin prick and light touch. CSF protein
PCR amplification of the six coding exons of MPZ was performedwas elevated to 169 mg%. NCV studies showed severe motor slow-
using the primer sets and conditions previously described (Roa eting (left ulnar nerve, 6.1 m/s; left common peroneal nerve, 7.2 m/s),
al., 1996). However, another exon 3 primer set that gives a slightlywith marked delay in distal latencies and severe slowing in spinal
larger PCR product was sometimes used, and the group of C. V. B.accessory nerve latency. Sensory nerve action potentials were ab-
sent in the left superficial peroneal, bilateral sural, left median, and used a different MPZ exon 5 primer set to perform the SSCP analysis.
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The sequence for the other MPZ exon 3 primer set is as follows: Charcot–Marie–Tooth neuropathy to the Duffy locus on chromo-
some 1. Am. J. Hum. Genet. 34, 388–394.exon 3 forward, 59-ATGGAGCTAAGCTTTGAC-39; exon 3 reverse,
59-CCCCTCCCAAACTGCTTC-39. The sequence for the other MPZ Blanquet-Grossard, F., Pham-Dinh, D., Dautigny, A., Latour, P.,
exon 5 primer set is as follows: exon 5 forward, 59-GGCCAAACGT Bonnebouche, C., Corbillon, E., Chazot, G., and Vandenberghe, A.
ACAGCAGTCT-39; exon 5 reverse, 59-TCTCCTTCCCATCTTGTCT (1995). Charcot–Marie–Tooth type 1B neuropathy: third mutation at
AGG-39. Heteroduplex analysis on mutation detection enhancement serine 63 codon in the major peripheral myelin glycoprotein P0 gene.
(MDE) acrylamide gels (FMC) was used to screen PCR-amplified Clin. Genet. 48, 281–283.
MPZ exons for the presence of a nucleotide change (Roa et al.,
Blanquet-Grossard, F., Pham-Dinh, D., Dautigny, A., Latour, P.,
1993b). SSCP analysis was performed as described (Nelis et al.,
Bonnebouche, C., Diraison, P., Chapon, F., Chazot, G., and Vanden-
1994b). berghe, A. (1996). Charcot–Marie–Tooth type 1B: a mutation at the
Direct sequencing was performed using single-stranded biotinyl- single glycosylation site in the major peripheral myelin glycoprotein
ated PCR products. Biotinylated PCR products were generated us- P0. Hum. Mut., in press.ing biotinylated forward or reverse primers. The biotinylated strand
Boylan, K.B., Ferriero, D.M., Greco,C.M., Sheldon, R.A., and Dew, M.was then isolated on streptavidin-conjugated beads (Dynal) as fol-
(1992). Congenital hypomyelination neuropathy with arthrogryposislows: 20 ml of PCR reaction (out of a 50 ml reaction volume) was
multiplex congenita. Ann. Neurol. 31, 337–340.combined with 20 ml of streptavidin magnetic beads. This mixture
Byers, P.H., Wallis, G.A., and Willing, M.C. (1991). Osteogenesiswas incubated at room temperature for 20 min. The magnetic beads
imperfecta: translation of mutation to phenotype. J. Med. Genet.were concentrated for 30 s using the Magnetic Particle Concentrator
28, 433–442.(MPC-E; Dynal). The supernatant was then removed and discarded.
The beads were resuspended in 100 ml of 0.15 M NaOH and incu- Charnas, L., Trapp, B., and Griffin, J. (1988). Congenital absence
bated at room temperature for 5 min. The concentration step was of peripheral myelin: abnormal Schwann cell development causes
then repeated, and the magnetic beads resuspend in 100 ml of 0.15 lethal arthrogryposis multiplex congenita. Neurology 38, 966–974.
M NaOH, 2 M NaCl in TE. Again the concentration step was repeated, Cheifetz, S., and Moscarello, M.A. (1985). Effect of bovine basic
and thebeads washed twice in 100ml of TE buffer. The concentration protein charge microheterogeneity on protein-induced aggregation
step was repeated once more, and the beads were resuspended in of unilamellar vesicles containing a mixture of acidic and neutral
7 ml of TE buffer. The resulting single-stranded biotinylated product phospholipids. Biochemistry 24, 1909–1914.
was then sequenced by dideoxy sequencing (Sequenase 2.0; United
Cheifetz, S., Boggs, J.M., and Moscarello, M.A. (1985). Increase inStates Biochemical), as described by the manufacturer. Fluorescent
vesicle permeability mediated by myelin basic protein: effect ofautomated sequencing was performed on cloned products in the
phosphorylation of basic protein. Biochemistry 24, 5170–5175.nucleic acids core in the Department of Molecular and Human Ge-
Ding, Y., and Brunden, K.R. (1994). The cytoplasmic domain of my-netics at Baylor College of Medicine.
elin glycoprotein P0 interacts with negatively charged phospholipidRestriction digestions were performed to confirm the presence
bilayers. J. Biol. Chem. 269, 10764–10770.of mutations in the different patients, except in patient 1040 in which
a restriction digest would not have been informative. For each diges- D’Urso, D., Brophy, P.J., Staugaitis, S.M., Gillespie, C.S., Frey, A.B.,
tion, 5 ml (10%) of the amplified PCR product was used as a sub- Stempak, J.G., and Colman, D.R. (1990). Protein zero of peripheral
strate. Five units of the desired enzyme was added to a 20 ml reaction nerve myelin: biosynthesis, membrane insertion, and evidence for
volume. Digestions were incubated for 3 hr at the temperature rec- homotypic interaction. Neuron 2, 449–460.
ommended by the manufacturer (New England Biolabs). HhaI, with Dyck, P.J., Chance, P., Lebo, R., and Carney, J.A. (1993). Hereditary
BsaHI as a control, was used for patients 511 and 1022; BslI, with motor and sensory neuropathies. In Peripheral Neuropathy, P.J.
BsaHI as a control, was used for patients 1047–1050; and BsoFI, Dyck, P.K. Thomas, et al., eds. (Philadelphia, Pennsylvania: W. B.
with HhaI as a control, was used for patient 987. Saunders Company), pp. 1094–1136.
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